Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2025
Download Free Sample Buy Now
Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025
Item added to cart!

Report Price : $4490.00

Pages : 250

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2025

By Drug Type (Monotherapy, Combination Therapy), By Line of Therapy (First-line Treatment, Second-line And Beyond), By End User (Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

• Programmed Death (PD)-1 Non-Small Cell Lung Cancer market size has reached to $25.23 billion in 2024

• Expected to grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%

• Growth Driver: Growing Use Of Personalized Treatments Boosting Market Growth Due To Improved Survival And Reduced Side Effects

• Market Trend: Innovation In Treatment Modalities With Accelerating Clinical Validation Of PD-1 Therapies For Non-Small Cell Lung Cancer

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) refers to a form of lung cancer where the tumor evades immune detection by exploiting the PD-1 pathway, a key immune checkpoint. PD-1 is a receptor on T cells that, when engaged by its ligands (PD-L1 or PD-L2), suppresses immune responses to prevent tissue damage. In NSCLC, tumors often overexpress PD-L1, leading to immune evasion and cancer progression.

The main type of programmed death (PD)-1 non-small cell lung cancer market includes monotherapy and combination therapy. Monotherapy means using only one type of drug to treat a disease, without combining it with other treatments. It is used for various lines of therapies, which include first-line treatment, second-line, and beyond, by varied end users such as hospitals, specialty cancer centers, academic and research institutes, and others.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Size and growth rate 2025 to 2029: Graph

What Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Size 2025 And Growth Rate?

The programmed death (PD)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $25.23 billion in 2024 to $27.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of non-small cell lung cancer, rising adoption of immunotherapy in developed nations, growing awareness about cancer screening, increasing approvals for monoclonal antibodies, and rising healthcare expenditure.

What Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Forecast?

The programmed death (PD)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing investments in cancer-specific infrastructure, expanding patient access to biologics in emerging markets, growing geriatric population globally, increasing reimbursement support for immunotherapies and rising clinical success rates of PD-1 inhibitors. Major trends in the forecast period include technological advancements in biomarker testing, developments in combination immunotherapy protocols, investment in personalized treatment strategies, research and development in novel PD-1 inhibitors and innovation in immune checkpoint blockade mechanisms.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmented?

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Is Driving The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market? Growing Use Of Personalized Treatments Boosting Market Growth Due To Improved Survival And Reduced Side Effects

The increasing adoption of personalized treatments is expected to propel the growth of the programmed death (PD)-1 non-small cell lung cancer market forward. Personalized treatments refer to medical approaches tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is due to the growing availability of genomic profiling and biomarker testing, as these technologies help identify specific mutations and biological markers, allowing clinicians to select therapies that are more likely to be effective for each individual. Personalized treatments help programmed death (PD)-1 non-small cell lung cancer (NSCLC) by tailoring therapies based on a patient’s genetic profile, tumor characteristics, and immune response. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023 compared to 6 in the year 2022. Therefore, the increasing adoption of personalized treatments is driving the growth of the programmed death (PD)-1 non-small cell lung cancer industry.

Who Are The Major Players In The Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

What Are The Key Trends Of The Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market? Innovation In Treatment Modalities With Accelerating Clinical Validation Of PD-1 Therapies For Non-Small Cell Lung Cancer

Major companies operating in the programmed death (PD)-1 non-small cell lung cancer market are focusing on conducting clinical trials of innovative therapies, such as monotherapy, to improve outcomes for patients. Monotherapy is a treatment approach that uses a single drug or therapy to treat a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical company, announced positive results from its Phase III HARMONi-2 trial evaluating Ivonescimab (AK112) in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer (NSCLC). The study met its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, highlighting the dual-targeted bispecific antibody's therapeutic potential.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market? BioNTech Acquired Biotheus To Strengthen Oncology Pipeline And Expand In Asia-Pacific

In February 2025, BioNTech SE, a Germany-based biotechnology company, acquired Biotheus Inc. for an undisclosed amount. Through this acquisition, BioNTech gained access to Biotheus’s lead asset, PM8002, a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF)-A, currently in late-stage clinical trials for non-small cell lung cancer and other solid tumors. Biotheus Inc. is a China-based provider of innovative antibody therapeutics that specializes in the development of multispecific biologics and immuno-oncology candidates for cancer treatment, including PD-1 therapies for non-small cell lung cancer (NSCLC).

What Is The Regional Outlook For The Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the acute care telemedicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Care Telemedicine Market?

The acute care telemedicine market includes revenues earned by entities by providing services like virtual emergency care, remote intensive care unit monitoring, tele-stroke evaluations, virtual hospitalist support, and real-time specialist consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry?

The programmed death (PD)-1 non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including programmed death (PD)-1 non-small cell lung cancer industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the programmed death (PD)-1 non-small cell lung cancer industry. This programmed death (PD)-1 non-small cell lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Programmed Death PD 1 Non Small Cell Lung Cancer Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $27.50 billion
Revenue Forecast In 2034 $38.26 billion
Growth Rate CAGR of 8.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered Drug Type, Line of Therapy, End User, Monotherapy, Combination Therapy
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Characteristics

3. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Trends And Strategies

4. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Rate Analysis

5.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Total Addressable Market (TAM)

6. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation

6.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy

Combination Therapy

6.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

First-line Treatment

Second-line And Beyond

6.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Cancer Centers

Academic And Research Institutes

Other End Users

6.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pembrolizumab (Keytruda)

Nivolumab (Opdivo)

Cemiplimab (Libtayo)

Toripalimab

Tislelizumab

Camrelizumab

Dostarlimab

Other Monotherapy Drug Types

6.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Programmed Death (PD)-1 Inhibitor And Chemotherapy

Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor

Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor

Programmed Death (PD)-1 Inhibitor And Targeted Therapy

Programmed Death (PD)-1 Inhibitor And Radiation Therapy

Triple Combination Therapy

Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine

Other Combination Drug Types

7. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional And Country Analysis

7.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

8.1. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

9.1. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

9.2. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

10.1. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

11.1. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

11.2. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

12.1. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

13.1. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

14.1. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

14.2. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

15.1. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

15.2. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

16.1. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

17.1. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

18.1. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

19.1. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

20.1. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

21.1. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

21.2. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

22.1. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

23.1. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

23.2. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

24.1. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

24.2. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

25.1. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

25.2. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

26.1. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

26.2. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

27.1. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

28.1. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

28.2. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

29.1. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

29.2. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape And Company Profiles

30.1. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape

30.2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc

31.2. Regeneron Pharmaceuticals Inc.

31.3. Incyte Corporation

31.4. Ono Pharmaceutical Co. Ltd.

31.5. BeiGene Ltd.

31.6. BioNTech SE

31.7. Shanghai Junshi Biosciences Co. Ltd.

31.8. MacroGenics Inc.

31.9. Akeso Inc.

31.10. Arcus Biosciences Inc.

31.11. Shandong Boan Biotechnology Co. Ltd.

31.12. CStone Pharmaceuticals

31.13. iTeos Therapeutics Inc.

31.14. Summit Therapeutics Inc.

31.15. Shanghai Henlius Biotech Inc.

32. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

34. Recent Developments In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

35. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market High Potential Countries, Segments and Strategies

35.1 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 77: Merck & Co. Inc. Financial Performance
  • Table 78: AbbVie Inc. Financial Performance
  • Table 79: Sanofi S.A. Financial Performance
  • Table 80: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 77: Merck & Co. Inc. Financial Performance
  • Figure 78: AbbVie Inc. Financial Performance
  • Figure 79: Sanofi S.A. Financial Performance
  • Figure 80: Novartis AG Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Read More About Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Read More About Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Read More About Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

Read More About Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2025 – By Product (Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab), By Distribution Channel (Hospital pharmacies, Retail pharmacie...

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Oth...

Small Cell Lung Cancer Therapeutics Global Market Report 2025 – By Drug Type (Atezolizumab, Topotecan, Lurbinectedin, Durvalumab, Methotrexate, Pembrolizumab), By Treatment Type (Chemotherapy, Targeted Therapy, Other Tre...

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Oth...

Lung Cancer Drugs Global Market Report 2025 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC))...

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Oth...

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Oth...

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Oth...

Frequently Asked Questions

Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) refers to a form of lung cancer where the tumor evades immune detection by exploiting the PD-1 pathway, a key immune checkpoint. PD-1 is a receptor on T cells that, when engaged by its ligands (PD-L1 or PD-L2), suppresses immune responses to prevent tissue damage. In NSCLC, tumors often overexpress PD-L1, leading to immune evasion and cancer progression. For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here

The Programmed Death PD 1 Non Small Cell Lung Cancer market major growth driver - Growing Use Of Personalized Treatments Boosting Market Growth Due To Improved Survival And Reduced Side Effects. For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here

The Programmed Death PD 1 Non Small Cell Lung Cancer market size has grown strongly in recent years. The programmed death (PD)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $25.23 billion in 2024 to $27.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of non-small cell lung cancer, rising adoption of immunotherapy in developed nations, growing awareness about cancer screening, increasing approvals for monoclonal antibodies, and rising healthcare expenditure. The programmed death (PD)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing investments in cancer-specific infrastructure, expanding patient access to biologics in emerging markets, growing geriatric population globally, increasing reimbursement support for immunotherapies and rising clinical success rates of PD-1 inhibitors. Major trends in the forecast period include technological advancements in biomarker testing, developments in combination immunotherapy protocols, investment in personalized treatment strategies, research and development in novel PD-1 inhibitors and innovation in immune checkpoint blockade mechanisms. For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here.

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc. . For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here.

Major trends in the Programmed Death PD 1 Non Small Cell Lung Cancer market include Innovation In Treatment Modalities With Accelerating Clinical Validation Of PD-1 Therapies For Non-Small Cell Lung Cancer. For further insights on the Programmed Death PD 1 Non Small Cell Lung Cancer market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon